Abstract

Regular lipid apheresis is a treatment modality for patients with severe drug resistant LDL-hypercholesterolemia or lipoprotein(a) elevation and premature atherosclerosis. A number of new approaches is currently being developed which can significantly decrease LDL-cholesterol levels alone or in combination with statins. If proven to be safe, these drugs may significantly reduce the necessity for regular lipid apheresis since more patients will achieve LDL-cholesterol treatment targets by drug therapy alone.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.